YUN WU

TitleAssociate Professor
InstitutionMD Anderson
DepartmentPathology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Park YM, Wu Y, Wei W, Yang WT. Primary neuroendocrine carcinoma of the breast: clinical, imaging, and histologic features. AJR Am J Roentgenol. 2014 Aug; 203(2):W221-30. PMID: 25055297.
      Citations: 10     Fields:    Translation:Humans
    2. Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014 Mar 04; 14:147. PMID: 24589259.
      Citations: 44     Fields:    Translation:HumansPHPublic Health
    3. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70. PMID: 24764583.
      Citations: 431     Fields:    Translation:HumansCells
    4. Wang J, Li D, Wang B, Wu Y. Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013 Sep; 141(2):213-24. PMID: 24036660.
      Citations: 13     Fields:    Translation:HumansCells
    5. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol. 2013 Oct; 24(10):2534-2542. PMID: 23729783.
      Citations: 8     Fields:    Translation:Humans
    6. Adrada B, Wu Y, Yang W. Hyperechoic lesions of the breast: radiologic-histopathologic correlation. AJR Am J Roentgenol. 2013 May; 200(5):W518-30. PMID: 23617519.
      Citations: 12     Fields:    Translation:Humans
    7. Sharaf Aldeen B, Feng J, Wu Y, Nassar Warzecha H. Molecular subtypes of ductal carcinoma in situ in African American and Caucasian American women: distribution and correlation with pathological features and outcome. Cancer Epidemiol. 2013 Aug; 37(4):474-8. PMID: 23639792.
      Citations: 2     Fields:    Translation:Humans
    8. Desai S, Liu Z, Yao J, Patel N, Chen J, Wu Y, Ahn EE, Fodstad O, Tan M. Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7). J Biol Chem. 2013 Mar 29; 288(13):9165-76. PMID: 23386620.
      Citations: 56     Fields:    Translation:HumansCells
    9. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J. 2013 Jan-Feb; 19(1):10-7. PMID: 23337751.
      Citations: 29     Fields:    Translation:Humans
    10. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8. PMID: 22895267.
      Citations: 3     Fields:    Translation:Humans
    11. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2012 Sep; 135(2):619-27. PMID: 22890751.
      Citations: 14     Fields:    Translation:Humans
    12. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, Medina D, Allred DC. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res. 2012 Sep 01; 72(17):4574-86. PMID: 22751464.
      Citations: 78     Fields:    Translation:HumansAnimalsCells
    13. Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst. 2011 Dec 21; 103(24):1871-83. PMID: 22034635.
      Citations: 47     Fields:    Translation:Humans
    14. Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology. 2011 Oct; 59(4):619-30. PMID: 22014043.
      Citations: 14     Fields:    Translation:Humans
    15. Adejolu M, Wu Y, Santiago L, Yang WT. Adenomyoepithelial tumors of the breast: imaging findings with histopathologic correlation. AJR Am J Roentgenol. 2011 Jul; 197(1):W184-90. PMID: 21700984.
      Citations: 4     Fields:    Translation:Humans
    16. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology. 2011 Jul; 59(1):106-15. PMID: 21668471.
      Citations: 14     Fields:    Translation:Humans
    17. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81. PMID: 21558518.
      Citations: 305     Fields:    Translation:Humans
    18. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, Liu B, Fodstad O, Chen J, Wu Y, Price JE, Tan M. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 2011 Jul 01; 71(13):4585-97. PMID: 21498634.
      Citations: 113     Fields:    Translation:HumansAnimalsCells
    19. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77. PMID: 21334720.
      Citations: 20     Fields:    Translation:HumansCells
    20. Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, Abraham S, Nayeemuddin K, Hunt K, Wu Y. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer. 2010 Oct 01; 116(19):4463-73. PMID: 20572042.
      Citations: 53     Fields:    Translation:Humans
    21. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163. PMID: 20121597.
      Citations: 1     Fields:    Translation:Humans
    22. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol. 2009 Apr; 33(4):534-41. PMID: 19047898.
      Citations: 16     Fields:    Translation:HumansCells
    23. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008 Dec; 16(6):530-4. PMID: 18776816.
      Citations: 19     Fields:    Translation:Humans
    24. Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S, Sun T, Zhou Y, Monaco P, Belmont J, Aderem A, Akira S, Strong R, Arlinghaus R. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene. 2008 Oct 16; 27(47):6110-9. PMID: 18663364.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    25. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008 Jan 15; 14(2):370-8. PMID: 18223211.
      Citations: 127     Fields:    Translation:Humans
    26. Nicolas MM, Wu Y, Middleton LP, Gilcrease MZ. Loss of myoepithelium is variable in solid papillary carcinoma of the breast. Histopathology. 2007 Nov; 51(5):657-65. PMID: 17927587.
      Citations: 8     Fields:    Translation:Humans
    27. Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, Allred DC. Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol. 2007 Jul; 171(1):252-62. PMID: 17591970.
      Citations: 44     Fields:    Translation:HumansCells
    28. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist. 2006 Sep; 11(8):868-77. PMID: 16951390.
      Citations: 64     Fields:    Translation:Humans
    29. Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res. 2006 Mar 15; 12(6):1721-7. PMID: 16551855.
      Citations: 8     Fields:    Translation:Humans
    30. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer. 2005 Dec; 12(4):1059-69. PMID: 16322343.
      Citations: 21     Fields:    Translation:Humans
    31. Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol. 2004 Dec; 95(3):570-5. PMID: 15581965.
      Citations: 9     Fields:    Translation:Humans
    32. Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Res. 2002 Jan 15; 62(2):386-90. PMID: 11809685.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    33. Abe JI, Che W, Yoshizumi M, Huang Q, Glassman M, Ohta S, Wu Y, Arlinghaus R, Berk BC. Bcr in vascular smooth muscle cells involvement of Ras and Raf-1 activation by Bcr. Ann N Y Acad Sci. 2001 Dec; 947:341-3. PMID: 11795286.
      Citations: 2     Fields:    Translation:Animals
    34. Che W, Abe J, Yoshizumi M, Huang Q, Glassman M, Ohta S, Melaragno MG, Poppa V, Yan C, Lerner-Marmarosh N, Zhang C, Wu Y, Arlinghaus R, Berk BC. p160 Bcr mediates platelet-derived growth factor activation of extracellular signal-regulated kinase in vascular smooth muscle cells. Circulation. 2001 Sep 18; 104(12):1399-406. PMID: 11560856.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    35. Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res. 2001 Jan 01; 61(1):138-44. PMID: 11196151.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    36. Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J, Arlinghaus RB. Bcr: a negative regulator of the Bcr-Abl oncoprotein. Oncogene. 1999 Aug 05; 18(31):4416-24. PMID: 10442632.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    37. Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B, Cong F, Goff SP, Wu Y, Arlinghaus R, Baltimore D, Gasser PJ, Park MS, Sung P, Lee EY. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem. 1999 Apr 30; 274(18):12748-52. PMID: 10212258.
      Citations: 73     Fields:    Translation:Cells
    38. Guo XY, Cuillerot JM, Wang T, Wu Y, Arlinghaus R, Claxton D, Bachier C, Greenberger J, Colombowala I, Deisseroth AB. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells. Oncogene. 1998 Aug 20; 17(7):825-33. PMID: 9779999.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    39. Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene. 1998 Jan 08; 16(1):141-6. PMID: 9467953.
      Citations: 5     Fields:    Translation:AnimalsCells
    40. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene. 1997 May 15; 14(19):2367-72. PMID: 9178913.
      Citations: 10     Fields:    Translation:AnimalsCells
    41. Liu J, Wu Y, Arlinghaus RB. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res. 1996 Nov 15; 56(22):5120-4. PMID: 8912843.
      Citations: 4     Fields:    Translation:AnimalsCells
    42. Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N, Groffen J, Arlinghaus RB. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol. 1996 Mar; 16(3):998-1005. PMID: 8622703.
      Citations: 12     Fields:    Translation:AnimalsCells
    43. Myofibroblastoma of the breast. European Journal of Radiology Extra. 73.
    44. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications. 7.
    45. Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene.
    46. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Annals of Surgical Oncology. 1-7.
    47. Prognostic and Predictive Factors of Invasive Breast Cancer. 187-206.
    48. EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape. Cancer Research. 76:1284-1296.
    49. Pretreatment neutrophil to lymphocyte ratio is associated with poor survival in patients with stage I-III non-small cell lung cancer. PLoS One. 11.
    50. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Modern Pathology.
    51. Molecular classification and testing of breast carcinoma.
    52. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent twist1 degradation. Cancer Research. 76:1451-1462.
    53. Nature Communications. 6.
    54. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 30:925-939.
    55. Xanthogranuloma of the breast. European Journal of Radiology Extra. 75.
    56. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. 22:194-201.
    57. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World Journal of Clinical Oncology. 7:387-394.
    58. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology.
    WU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (257)
    Explore
    _
    Co-Authors (45)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _